Payment overview · 2025
General Payments
$844.86
35 reported records · 9 companies
Healthcare provider profile · identity verified
Nabil Salloum Feghali, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CANOGA PARK, CA · NPI 1982787057
Verified facts
What the public records show
CMS Open Payments records show Nabil Salloum Feghali, MD received $844.86 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 67.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $569.77 | 67.4% | 23 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.11 | 7.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.86 | 6.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.27 | 4.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.78 | 3.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.70 | 2.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.91 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.30 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.16 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $844.86 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $413.93 | 16 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $100.60 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.11 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.86 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.23 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 16 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 34 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 309 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
309 | 64 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
186 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1027 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 833 | 200 |
| Metformin Hcl | Metformin Hcl | 675 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 648 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 616 | 153 |
| Gabapentin | Gabapentin | 530 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 515 | 123 |
| Tamsulosin Hcl | Tamsulosin Hcl | 514 | 123 |
| Clopidogrel | Clopidogrel Bisulfate | 507 | 104 |
| Furosemide | Furosemide | 470 | 108 |
| Losartan Potassium | Losartan Potassium | 443 | 93 |
| Eliquis | Apixaban | 416 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 403 | 95 |
| Omeprazole | Omeprazole | 392 | 84 |
| Montelukast Sodium | Montelukast Sodium | 377 | 79 |
| Finasteride | Finasteride | 362 | 76 |
| Linzess | Linaclotide | 309 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 290 | 81 |
| Trazodone Hcl | Trazodone Hcl | 289 | 61 |
| Simvastatin | Simvastatin | 270 | 60 |
| Clonidine Hcl | Clonidine Hcl | 269 | 72 |
| Vascepa | Icosapent Ethyl | 266 | 48 |
| Azithromycin | Azithromycin | 254 | 186 |
| Carvedilol | Carvedilol | 245 | 41 |
| Donepezil Hcl | Donepezil Hcl | 241 | 47 |
| Lisinopril | Lisinopril | 223 | 54 |
| Meloxicam | Meloxicam | 223 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 46 |
| Allopurinol | Allopurinol | 222 | 45 |
| Celecoxib | Celecoxib | 214 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 208 | 42 |
| Famotidine | Famotidine | 198 | 62 |
| Tramadol Hcl | Tramadol Hcl | 195 | 55 |
| Alendronate Sodium | Alendronate Sodium | 191 | 44 |
| Atenolol | Atenolol | 186 | 49 |
| Jardiance | Empagliflozin | 186 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 34 |
| Ozempic | Semaglutide | 185 | 35 |
| Tradjenta | Linagliptin | 182 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 31 |
| Myrbetriq | Mirabegron | 178 | 26 |
| Mirtazapine | Mirtazapine | 174 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 167 | 54 |
| Memantine Hcl | Memantine Hcl | 167 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 163 | 49 |
| Sertraline Hcl | Sertraline Hcl | 163 | 32 |
| Ezetimibe | Ezetimibe | 162 | 34 |
| Glimepiride | Glimepiride | 161 | 30 |
| Januvia | Sitagliptin Phosphate | 157 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 45 |
| Potassium Chloride | Potassium Chloride | 154 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 153 | 37 |
| Meclizine Hcl | Meclizine Hcl | 152 | 41 |
| Topiramate | Topiramate | 150 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 148 | 68 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 148 | 35 |
| Cephalexin | Cephalexin | 144 | 109 |
| Buspirone Hcl | Buspirone Hcl | 141 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 136 | 49 |
| Icosapent Ethyl | Icosapent Ethyl | 133 | 40 |
| Valsartan | Valsartan | 128 | 29 |
| Baclofen | Baclofen | 121 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 39 |
| Benazepril Hcl | Benazepril Hcl | 118 | 29 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 111 | 23 |
| Glipizide | Glipizide | 104 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 33 |
| Metoclopramide Hcl | Metoclopramide Hcl | 103 | 32 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 102 | 14 |
| Ibuprofen | Ibuprofen | 101 | 32 |
| Spironolactone | Spironolactone | 101 | 23 |
| Alprazolam | Alprazolam | 99 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 99 | 24 |
| Levetiracetam | Levetiracetam | 99 | 14 |
| Bumetanide | Bumetanide | 97 | 20 |
| Lorazepam | Lorazepam | 95 | 31 |
| Naproxen | Naproxen | 94 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 15 |
| Lactulose | Lactulose | 91 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 88 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 87 | 19 |
| Fenofibrate | Fenofibrate | 86 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 86 | 16 |
| Bupropion Xl | Bupropion Hcl | 85 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 85 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 61 |
| Colchicine | Colchicine | 84 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 16 |
| Ketoconazole | Ketoconazole | 81 | 30 |
| Pregabalin | Pregabalin | 80 | 19 |
| Trulicity | Dulaglutide | 79 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 78 | 17 |
| Clonazepam | Clonazepam | 78 | 19 |
| Entresto | Sacubitril/Valsartan | 78 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 78 | 18 |
| Mupirocin | Mupirocin | 77 | 56 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | 19 |
| Prednisone | Prednisone | 74 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 71 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 20 |
| Mounjaro | Tirzepatide | 69 | 11 |
| Irbesartan | Irbesartan | 68 | 14 |
| Xarelto | Rivaroxaban | 67 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 54 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 32 |
| Terazosin Hcl | Terazosin Hcl | 60 | 11 |
| Lovastatin | Lovastatin | 58 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 47 |
| Ondansetron Odt | Ondansetron | 57 | 15 |
| Latanoprost | Latanoprost | 56 | 11 |
| Constulose | Lactulose | 54 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 54 | 14 |
| Prolia | Denosumab | 54 | 34 |
| Sucralfate | Sucralfate | 54 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 11 |
| Cyclosporine | Cyclosporine | 52 | suppressed |
| Procto-Med Hc | Hydrocortisone | 52 | suppressed |
| Gemfibrozil | Gemfibrozil | 51 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 14 |
| Synthroid | Levothyroxine Sodium | 51 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 14 |
| Lidocaine | Lidocaine | 49 | 16 |
| Enalapril Maleate | Enalapril Maleate | 48 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 11 |
| Temazepam | Temazepam | 47 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Methimazole | Methimazole | 43 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | 11 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Fluconazole | Fluconazole | 40 | 24 |
| Metformin Er Gastric | Metformin Hcl | 40 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 40 | 11 |
| Ciclopirox | Ciclopirox | 39 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 14 |
| Levofloxacin | Levofloxacin | 39 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Mometasone Furoate | Mometasone Furoate | 38 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 20 |
| Amoxicillin | Amoxicillin | 37 | 33 |
| Methenamine Hippurate | Methenamine Hippurate | 37 | 11 |
| Metolazone | Metolazone | 37 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 11 |
| Metronidazole | Metronidazole | 35 | 26 |
| Diltiazem Hcl | Diltiazem Hcl | 34 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 26 |
| Fluocinonide | Fluocinonide | 34 | suppressed |
| Gemtesa | Vibegron | 34 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 34 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 14 |
| Repaglinide | Repaglinide | 32 | suppressed |
| Acarbose | Acarbose | 31 | suppressed |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Primidone | Primidone | 29 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 24 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 28 | 25 |
| Pilocarpine Hcl | Pilocarpine Hcl | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Lacosamide | Lacosamide | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | 12 |
| Roflumilast | Roflumilast | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 13 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 25 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Hydroxyurea | Hydroxyurea | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | 17 |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Zileuton Er | Zileuton | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | 12 |
| Flavoxate Hcl | Flavoxate Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | 11 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Fluorometholone | Fluorometholone | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $844.86 · 35 records | ABBVIE INC. | BREZTRI, CREON, FREESTYLE LIBRE 3, GEMTESA, LINZESS, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, TRULANCE, UBRELVY, VRAYLAR, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error